| 1 |
A Study to Evaluate Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment |
Esophageal Squamous Cell Carcinoma |
Drug: Paclitaxel|Drug: Irinotecan|Biological: Pembrolizumab|Biological: MK-4830|Drug: Lenvatinib |
Merck Sharp & Dohme LLC |
Phase 1|Phase 2 |
NCT05319730 |
2023-05-05 |
| 2 |
A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors |
Carcinoma, Non-Small-Cell Lung|Carcinoma, Renal Cell|Esophageal Squamous Cell Carcinoma|Squamous Cell Carcinoma of Head and Neck |
Biological: QEQ278 |
Novartis Pharmaceuticals|Novartis |
Phase 1 |
NCT05462873 |
2023-04-04 |
| 3 |
Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP) |
Primary Immune Thrombocytopenia (ITP) |
Biological: Ianalumab|Drug: Placebo|Drug: Corticosteroids |
Novartis Pharmaceuticals|Novartis |
Phase 3 |
NCT05653349 |
2023-03-06 |
| 4 |
Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1) |
Systemic Lupus Erythematosus |
Drug: Ianalumab|Drug: Placebo |
Novartis Pharmaceuticals|Novartis |
Phase 3 |
NCT05639114 |
2023-03-02 |
| 5 |
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) |
Diffuse Large B-Cell Lymphoma |
Drug: Epcoritamab|Drug: Cyclophosphamide|Drug: Rituximab|Drug: Vincristine|Drug: Doxorubicin|Drug: Prednisone |
AbbVie|Genmab |
Phase 3 |
NCT05578976 |
2023-02-08 |
| 6 |
A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids |
Primary Immune Thrombocytopenia |
Biological: Ianalumab|Drug: Eltrombopag|Drug: Placebo |
Novartis Pharmaceuticals|Novartis |
Phase 3 |
NCT05653219 |
2023-02-02 |
| 7 |
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas |
Small Cell Lung Cancer|Neuroendocrine Carcinoma |
Drug: RO7616789|Drug: Tocilizumab |
Hoffmann-La Roche |
Phase 1 |
NCT05619744 |
2023-01-23 |
| 8 |
Phase IIIb, Open-label, Multi-center Study to Evaluate Safety, Tolerability and Efficacy of OAV101 Administered Intrathecally to Participants With SMA Who Discontinued Treatment With Nusinersen or Risdiplam |
Spinal Muscular Atrophy |
Genetic: OAV101 |
Novartis Pharmaceuticals|Novartis |
Phase 3 |
NCT05386680 |
2023-01-12 |
| 9 |
Safety and Immunogenicity of V116 in Vaccine-naïve Japanese Older Adults (V116-009, STRIDE-9) |
Pneumococcal Disease |
Biological: V116|Biological: PPSV23 |
Merck Sharp & Dohme LLC |
Phase 3 |
NCT05633992 |
2023-01-10 |
| 10 |
A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia |
Warm Autoimmune Hemolytic Anemia (wAIHA) |
Biological: Ianalumab|Drug: Placebo |
Novartis Pharmaceuticals|Novartis |
Phase 3 |
NCT05648968 |
2022-12-30 |
이 누리집은 대한민국 공식 전자정부 누리집입니다.